Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.

Wurster, Sebastian; Watowich, Stephanie S; Kontoyiannis, Dimitrios P

Wurster, Sebastian; Watowich, Stephanie S; Kontoyiannis, Dimitrios P.

Afiliación

Wurster S; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Watowich SS; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Kontoyiannis DP; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Front Immunol ; 13: 1018202, 2022.

Article en En | MEDLINE | ID: mdl-36389687

Asunto(s)

Micosis; Neoplasias; Animales; Antifúngicos/uso terapéutico; Inmunoterapia; Factores Inmunológicos/uso terapéutico; Neoplasias/tratamiento farmacológico; Neoplasias/patología; Micosis/tratamiento farmacológico; Microambiente Tumoral

Palabras clave

T cells; aspergillosis; candidiasis; checkpoint inhibitors; fungal sepsis; immune exhaustion; immunotherapy; mucormycosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Micosis / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google